Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease
暂无分享,去创建一个
P. Bauer | D. Berg | O. Riess | J. Spiegel | G. Becker | U. Walter | I. Csoti | A. Bornemann | J. Pahnke | H. Hochstrasser | S. Behnke | B. Zeiler | Peter O. Bauer | I. Csóti
[1] P. Bauer,et al. Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra , 2003, Neuroscience Letters.
[2] S. David,et al. Glycosylphosphatidylinositol-anchored Ceruloplasmin Is Required for Iron Efflux from Cells in the Central Nervous System* , 2003, Journal of Biological Chemistry.
[3] H. Miyajima,et al. Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. , 2002, Blood cells, molecules & diseases.
[4] U. Bonuccelli,et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. , 2002, Blood.
[5] Jean-Pierre Julien,et al. Ceruloplasmin Regulates Iron Levels in the CNS and Prevents Free Radical Injury , 2002, The Journal of Neuroscience.
[6] M. Won,et al. The ceruloplasmin and hydrogen peroxide system induces α-synuclein aggregation in vitro , 2002 .
[7] Daniela Berg,et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.
[8] R. Benecke,et al. Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease , 2002, Journal of Neural Transmission.
[9] H. Miyajima,et al. Cerebellar ataxia associated with heteroallelic ceruloplasmin gene mutation , 2001, Neurology.
[10] Daniela Berg,et al. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings , 2001, Journal of Neurology.
[11] Y. Ke,et al. Rethinking the role of ceruloplasmin in brain iron metabolism , 2001, Brain Research Reviews.
[12] H. Miyajima,et al. Defective electron transfer in complexes I and IV in patients with aceruloplasminemia , 2000, Journal of the Neurological Sciences.
[13] P. Riederer,et al. Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.
[14] A. Nakamura,et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients , 2000, Journal of the Neurological Sciences.
[15] H. Miyajima,et al. Aceruloplasminemia with a novel mutation associated with parkinsonism , 2000, Neurogenetics.
[16] S. David,et al. Alternative RNA Splicing Generates a Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin in Mammalian Brain* , 2000, The Journal of Biological Chemistry.
[17] J. Gitlin,et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[18] G Becker,et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound , 1999, Neurology.
[19] J. Snaedal,et al. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. , 1999, Pharmacology & toxicology.
[20] T. Kawanami,et al. Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain , 1999, Neurology.
[21] G Becker,et al. Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.
[22] C. Ríos,et al. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease , 1999, Neuroscience Letters.
[23] E. Masliah,et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .
[24] M. Ronaghi,et al. A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.
[25] P. Fox,et al. Role of ceruloplasmin in cellular iron uptake. , 1998, Science.
[26] B. N. Patel,et al. A Novel Glycosylphosphatidylinositol-anchored Form of Ceruloplasmin Is Expressed by Mammalian Astrocytes* , 1997, The Journal of Biological Chemistry.
[27] J. Gitlin,et al. Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. , 1996, Human molecular genetics.
[28] R. MacGillivray,et al. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[29] G Becker,et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography , 1995, Neurology.
[30] Y. Kagawa,et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.
[31] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[32] T. Gasser. Overview of the genetics of parkinsonism. , 2003, Advances in neurology.
[33] J. Gitlin,et al. Ceruloplasmin metabolism and function. , 2002, Annual review of nutrition.
[34] M. Won,et al. The ceruloplasmin and hydrogen peroxide system induces alpha-synuclein aggregation in vitro. , 2002, Biochimie.
[35] D. Berg,et al. Brain iron pathways and their relevance to Parkinson's disease. , 2001, Journal of neurochemistry.